On March 17, 2024 Infinitopes reported the company collaborating with the leading mass spectrometry technology company Bruker to develop a world leading immunopeptidomic based antigen discovery platform (Press release, Infinitopes, MAR 17, 2024, View Source [SID1234648454]). In a recent poster, Infinitopes showcase their state-of-the-art sample preparation capabilities in synergy with the latest high-sensitivity mass spectrometry technology from Bruker. Building on Inifinitopes’ proprietary antigen purification strategy Bruker optimise the performance of their new timsTOF Ultra mass spectrometer providing a highly sensitive platform for antigen discovery. Bruker fine-tuned their instrument parameters to enable identification of thousands of peptide antigens from just 1 million melanoma cells. This development paves the way for cancer antigen discovery directly from patient biopsies, overcoming a critical unmet need for target discovery in the field of immuno-oncology. Dr. Rob Parker, Lead Scientist Discovery Immunomics of Infinitopes, commented:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to see our R&D capabilities drastically expanded through our unique collaboration with Bruker. Bruker’s commitment toward ultra-sensitive discovery immunopeptidomics will accelerate Infinitopes growth and provide unique benefit to our existing and future and partners, with our enhanced R&D output positioning Infinitopes as a leading force in cancer antigen discovery".